Unlocking Freedom in Parkinson's: Nourianz (Istradefylline) – An Add-On Breakthrough for 'Off' Episo
- OLCIAS
- Jul 5, 2023
- 4 min read
Talk Title: Unlocking Freedom in Parkinson's: Nourianz (Istradefylline) – An Add-On Breakthrough for 'Off' Episodes
Author: Dr. Mohammed Quader Naseer Kaloji Narayana Rao University of Health Sciences,
India
Dearbon Cardiology Hospital (Externship)
Michigan, US Email ID: mdquader59@gmail.com Volume: Parkinson's Disease 2023_CN37_AA04 The International Live Conference on Parkinson's Disease Date: July 15, 2023 Time: 8 PM Indian Standard Time Location: Online Conference Theme: The Future of Parkinson's Disease Research and Clinical Practice Abstract: Description:
It is a neurodegenerative disorder that primarily affects the motor system, characterized by the gradual loss of dopamine-producing cells in the brain, particularly in an area called the substantia nigra. Dopamine is a crucial neurotransmitter for coordinating movement.
The exact cause of Parkinson's disease is not fully understood but is believed to involve a combination of genetic and environmental factors. Age is the most significant risk factor, with the majority of cases occurring in individuals over the age of 60. However, early-onset Parkinson's can also occur in younger individuals.
Diagnosis of Parkinson's disease is based on a clinical assessment of symptoms and medical history. There are currently no specific laboratory tests or imaging studies that can definitively confirm the disease. Treatment options aim to alleviate symptoms, improve quality of life, and slow down disease progression, which may include medication therapy, physical therapy, speech therapy, and in some cases, surgical interventions such as deep brain stimulation.
Indications and Usage:
Nourianz (istradefylline) tablets are indicated as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. "Off" episodes refer to periods when the effectiveness of levodopa/carbidopa medications diminishes, leading to an exacerbation of PD symptoms such as tremor and difficulty walking. Nourianz is intended to improve motor function and reduce the frequency and severity of "off" episodes in PD patients. It is important to carefully follow the recommended dosing guidelines and individualize treatment based on the patient's response.
Dosage Forms and Strengths:
Nourianz (istradefylline) is available in the form of oral tablets for administration. The research papers indicate that Nourianz is available in two different forms:
- 20 mg Tablets: These tablets contain 20 mg of Istradefylline as the active ingredient and are typically used for the initial dosing and maintenance phase of treatment.
- 40 mg Tablets: These tablets contain 40 mg of Istradefylline as the active ingredient and may be used in cases where a higher dose is required after initial dosing and titration. Contraindications: None (As of now)
Dosage and Administration:
Dosage and Administration of Nourianz (Istradefylline) based on available research papers:
1. Initial Dosing: According to research papers, the recommended initial dose of Nourianz is 20 mg once daily. It is administered orally as a tablet and can be taken with or without food. The initial dose is independent of the patient's creatinine clearance or age.
2. Titration: If necessary, the dose of Nourianz can be increased to 40 mg once daily after a minimum of 1 week at the initial dose, as per research papers. The decision to titrate the dose should be based on the individual patient's response and tolerability. Close monitoring of the patient's response is crucial during the titration phase.
3. Maintenance Dose: After titration, the maintenance dose of Nourianz is typically 20 mg or 40 mg once daily, depending on the patient's response and tolerability. Research papers emphasize the importance of individualized treatment and finding the lowest effective dose for each patient.
4. Individualization of Dosage: It is crucial to individualize the dosage of Nourianz, as it may vary based on factors such as the patient's response, tolerability, and concomitant medications. Healthcare professionals should carefully assess and adjust the dosage to optimize treatment outcomes.
5. Route of Administration: Nourianz is administered orally as a tablet, as confirmed by research papers.
6. Adherence to Treatment: Consistent adherence to the prescribed dosage of Nourianz is essential for optimal treatment outcomes. Patient education regarding adherence and following the prescribed dosing schedule accurately is emphasized in research papers.
7. Monitoring and Adjustments: Regular monitoring of the patient's response to Nourianz is crucial. Healthcare professionals should closely monitor the patient's clinical status, including motor function assessment and the frequency and severity of "off" episodes. Dosage adjustments should be made based on the individual patient's response and tolerability, considering the benefit-risk profile.
MOA: Nourianz acts as a selective antagonist of adenosine A2A receptors, predominantly expressed in the basal ganglia, a brain region involved in motor control. By blocking these receptors, Nourianz modulates adenosine-mediated signaling pathways and enhances dopaminergic transmission in the striatum. This mechanism of action is believed to alleviate the symptoms of Parkinson's disease by reducing the inhibitory influence of adenosine on dopamine release, a crucial neurotransmitter for motor function. Nourianz's selective targeting of A2A receptors minimizes unwanted side effects associated with non-selective adenosine receptor antagonism. Research papers indicate that modulating adenosine A2A receptors plays a pivotal role in improving motor function and mitigating "off" episodes in Parkinson's disease patients. However, further research is needed to fully elucidate the intricate molecular mechanisms underlying the therapeutic effects of Nourianz and explore its potential in optimizing treatment outcomes for individuals with Parkinson's disease.
1. Nourianz (istradefylline) [Prescribing Information]. Woodcliff Lake, NJ: Kyowa Kirin, Inc.; February 2022.
2. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18(2):145-154.
3. Hauser RA, Aminoff MJ, Isaacson SH, et al. Patient-reported outcomes
in a phase 3 randomized controlled trial of levodopa inhalation powder in Parkinson's disease-associated motor fluctuations. J Parkinsons Dis. 2020;10(4):1529-1543.
4. Isaacson SH, Ondo WG, Lew MF, et al. Long-term safety and efficacy of levodopa inhalation powder (CVT-301) in Parkinson's disease subjects experiencing off periods: results of the open-label phase 3b study. J Parkinsons Dis. 2021;11(1):275-286.
5. Stocchi F, Rascol O, Hauser RA, et al. CVT-301 (levodopa inhalation powder) for treatment of Parkinson's disease-related motor fluctuations: results of the open-label safety extension phase of a phase 3 clinical trial. J Parkinsons Dis. 2020;10(3):999-1006.
6. Mizuno Y, Hattori N, Kondo T, et al. The efficacy and safety of istradefylline as an adjunctive treatment to levodopa in Japanese patients with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2010;25(5):716-722.
Biography:
Dr. Quader Naseer Mohammed is a dedicated medical professional currently serving as a medical intern and pursuing an externship at Dearborn Cardiology Hospital in Michigan (current designation). With a passion for medicine and a commitment to furthering medical knowledge, they have been actively involved in various national and international conferences. Dr. Mohammed is looking forward to being a part of this conference as they continue their journey of professional development and contribute to the advancement of medical science.
